Harvard Bioscience (NASDAQ:HBIO) Director Purchases $62,499.75 in Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO) Director William Snider purchased 12,525 shares of the stock in a transaction on Monday, March 16th. The stock was acquired at an average cost of $4.99 per share, for a total transaction of $62,499.75. Following the completion of the acquisition, the director owned 23,525 shares of the company’s stock, valued at $117,389.75. The trade was a 113.86% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

William Snider also recently made the following trade(s):

• On Tuesday, March 17th, William Snider purchased 8,475 shares of Harvard Bioscience stock. The shares were bought at an average cost of $4.85 per share, for a total transaction of $41,103.75.

Harvard Bioscience Stock Performance

NASDAQ HBIO opened at $5.27 on Friday. The firm has a market capitalization of $23.56 million, a P/E ratio of -0.41 and a beta of 1.51. The stock has a 50-day simple moving average of $5.55 and a two-hundred day simple moving average of $5.66. The company has a debt-to-equity ratio of 2.61, a quick ratio of 0.41 and a current ratio of 2.20. Harvard Bioscience, Inc. has a fifty-two week low of $2.81 and a fifty-two week high of $9.50.

Wall Street Analyst Weigh In

Several equities research analysts have commented on HBIO shares. New Street Research set a $6.00 price objective on Harvard Bioscience in a research report on Friday, March 13th. Wall Street Zen lowered shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Research upgraded shares of Harvard Bioscience to a “hold” rating in a research note on Thursday, December 11th. Benchmark lowered their price target on shares of Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating on the stock in a report on Friday, March 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Harvard Bioscience presently has an average rating of “Hold” and an average price target of $6.00.

Institutional Trading of Harvard Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its stake in shares of Harvard Bioscience by 44.4% during the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after buying an additional 11,948 shares during the period. Acadian Asset Management LLC grew its stake in Harvard Bioscience by 7.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock valued at $606,000 after acquiring an additional 78,276 shares during the period. Strs Ohio purchased a new stake in Harvard Bioscience in the 1st quarter worth $117,000. Marshall Wace LLP purchased a new stake in Harvard Bioscience in the 2nd quarter worth $61,000. Finally, Jane Street Group LLC raised its position in Harvard Bioscience by 491.9% during the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 58,785 shares during the period. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.